Editas Medicine Inc (EDIT)

NASDAQ
15.94
-0.38(-2.33%)
Pre Market
15.83
-0.11(-0.69%)
- Real-time Data
  • Volume:
    1,663,528
  • Day's Range:
    15.31 - 16.26
  • 52 wk Range:
    9.59 - 73.03

EDIT Overview

Prev. Close
16.32
Day's Range
15.31-16.26
Revenue
31.8M
Open
16.22
52 wk Range
9.59-73.03
EPS
-2.7
Volume
1,663,528
Market Cap
1.1B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,727,203
P/E Ratio
-6.04
Beta
2.02
1-Year Change
-73.42%
Shares Outstanding
68,719,250
Next Earnings Date
Nov 09, 2022
What is your sentiment on Editas Medicine?
or
Market is currently closed. Voting is open during market hours.

Editas Medicine Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Editas Medicine Inc Analysis

Editas Medicine Inc Company Profile

Editas Medicine Inc Company Profile

Employees
264

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellSell
Technical IndicatorsStrong SellStrong BuyStrong SellSellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell
  • Bullish
    0
    • I waited for over a year to come to what I think is a steal. I thought it was never going to happen, honestly. Haha. Got some nice swing trades though. Hoarded a lot below 15. I hope this is a bottom. If not, oh well. Personally, I think this is a
      0
      • mk9>98
        0
    • this company's stock price needs to start moving in the upward direction!
      1
      • the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.The Company will present a poster on its new method to drive high-level constitutive CD16 expression on the surface of iPSC-derived natural ***(iNK) cells through transgene knock-in (KI) at the GAPDH locus using an Editas-engineered AsCas12a. New preclinical data demonstrated that CD16 KI confers significantly increased cytotoxic activity in iNK cells against tumor cells compared with wild type iNK cells.
        1
        • this 37 dollar price point seems to me a very strong support.
          0
          • is it worthy to invest in this stock?
            0
            • No
              0
          • I don't get it. Fantastic results, and the shareprice drops like a rock!?
            0
            • well, now it is looking like a buy at 38 dollar. There is a very strong trendline there
              0
          • Today is the day.
            0
            • For what exacty !!!
              0
            • for positive research results on low and mid dose + a sell off xD
              0
          • ark invest sold 90,000 share of editas
            0
            • Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET. Editas Medicine, a leading genome editing company, announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration
              0
              • Results on september 29th , not september 10 th
                0